RT Journal Article
SR Electronic
T1 A rare genetic disorder provides insights into mechanisms of early-onset neurodegeneration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.22.23290124
DO 10.1101/2023.05.22.23290124
A1 Badja, Cherif
A1 Momen, Sophie
A1 Koh, Gene Ching Cheik
A1 Boushaki, Soraya
A1 Roumeliotis, Theodoros I.
A1 Kozik, Zuza
A1 Jones, Ian
A1 Bousgouni, Vicky
A1 Dias, João M. L.
A1 Krokidis, Marios G.
A1 Young, Jamie
A1 Chen, Hongwei
A1 Yang, Ming
A1 Docquier, France
A1 Memari, Yasin
A1 Valcarcel-Jimenez, Lorea
A1 Gupta, Komal
A1 Kong, Li Ren
A1 Fawcett, Heather
A1 Robert, Florian
A1 Zhao, Salome
A1 Degasperi, Andrea
A1 Davies, Helen
A1 Harris, Rebecca
A1 Frezza, Christian
A1 Chatgilialoglu, Chryssostomos
A1 Sarkany, Robert
A1 Lehmann, Alan
A1 Bakal, Chris
A1 Choudhary, Jyoti
A1 Fassihi, Hiva
A1 Nik-Zainal, Serena
YR 2023
UL http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290124.abstract
AB Xeroderma pigmentosum (XP) is characterized by defective repair of ultraviolet radiation(UVR)-induced DNA damage. Patients have UVR hypersensitivity and increased skin cancer risk. Effective photoprotection has reduced childhood cancer-related deaths, but revealed adolescence-onset neurodegeneration, arising through unknown mechanisms. Here, we investigate XP neurodegeneration using pluripotent stem cells derived from XP patients and healthy relatives, performing functional multi-omics on samples during neuronal differentiation. We find endoplasmic reticulum stress is upregulated, preceded by oxidative stress, causing substantial 5’,8-cyclopurine and 8-oxopurine DNA damage. Critically, XP neurons exhibit inappropriate downregulation of the protein clearance ubiquitin-proteasome system (UPS). Chemical enhancement of UPS activity improves phenotypes, albeit inadequately, implying that early detection/prevention strategies are necessary to produce clinically impactful outcomes. Thus, we develop an early detection assay predicting neurodegeneration in at-risk patients.Competing Interest StatementSNZ holds patents on mutational signature-based clinical algorithms not relevant to the research presented in this paper. The other authors declare no competing interests. All other authors declared no competing interest.Funding StatementWellcome PhD fellowship WT216339/Z/19/Z (to S.M)Cancer Research UK (CRUK) Advanced Clinician Scientist Award C60100/A23916 (to S.N.Z)Dr Josef Steiner Cancer Research Award 2019 (to S.N.-Z)Basser Gray Prime Award 2020 (to S.N.-Z)CRUK Pioneer Award C60100/A23433 (to S.N.-Z)CRUK Grand Challenge Award C60100/A25274 (to S.N.-Z)CRUK Early Detection Project Award C60100/A27815 (to S.N.-Z)National Institute of Health Research (NIHR) Research Professorship NIHR301627 (to S.N.Z)NIHR Cambridge Biomedical Research Centre BRC-1215-20014 (to S.N.-Z)CRUK Centre grant C309/A25144 (to T.I.R, J.C)Long-term FEBS fellowship (to L.V.-J)CRUK Programme Foundation award C51061/A27453 (to C.F)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:-Research Ethics Committee in England (REC: Norfolk NRES Committee; REC reference 13/EE/0302)gave ethical approval for this work.-Scotland A Research Ethics Committee (REC reference 14/SS/0096) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors